Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 30 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Ibrutinib ESMO Highlights the Importance of Prioritising the Fight Against Cancer in Its Response to the Public Consultation on the EU4Health 2026 Work Programme ESMO Urges EU Policymakers to Protect the Wellbeing of the Oncology Workforce MOST POPULAR New lung cancer treatment combo approved on NHS in England January 12, 2022 ¿Pueden confundirse los síntomas del cáncer con la menopausia? November 1, 2022 Mom Is Warning Other Parents After Her Son Was Bit By... May 24, 2019 How longer waiting times are impacting teens and young adults April 27, 2023 Load more HOT NEWS Moving target – retrotransposable elements and cancer ASCO 2023 roundup: Blood tests, drugs and exercise How CRISPR is Changing Cancer Research and Treatment EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab
